LAVAL, CANADA -- (MARKET WIRE) -- October 11, 2006 -- BioSyntech, Inc. ("BioSyntech" or the "Company") (TSX VENTURE: BSY) announced today that on September 20, 2006, it received a Notice of Allowance from the US Patent and Trademark Office on their key BST-CarGel® patent entitled, "Composition and method for the repair and regeneration of cartilage and other tissues". BST-CarGel®, the Company's lead product, was designed to address the enormous clinical problem of cartilage damage and the inadequacies of current treatment options. The results of a major pre-clinical study, published in December 2005 in the prestigious Journal of Bone and Joint Surgery showed scientifically that BST-CarGel® regenerates more, higher quality cartilage than a common surgical procedure called microfracture.
